Board of Directors

Mr. Davitian has extensive experience in the life sciences and biotech industry, including several successful financing and M&A transactions. He has served as a partner at Omega Funds since 2020. Previously, Mr. Davitian served as Senior Vice President and Managing Director at Sanofi Ventures, which he joined in 2010 as Vice President, Deputy Global Head, Business Development. Over his seven-year tenure at Sanofi Ventures, the company invested in 28 new companies and generated 14 exits (12 NASDAQ IPOs, one trade sale and one option deal). Prior to joining Sanofi, Mr. Davitian held Chief Executive Officer, Chief Financial Officer and other leadership roles at Fovea Pharmaceuticals (which was sold to Sanofi in 2009 in a €370 million cash transaction), Neurotech Pharmaceuticals, Transgene and Institut Mérieux (now Sanofi Pasteur). Mr. Davitian earned his Master of Science from the Emlyon Business School and his Executive MBA from the Wharton School of Business at the University of Pennsylvania.

Mr. Enright is a Managing Director and Founder of Longitude Capital. Prior to joining Longitude, Mr. Enright was a Managing Director of Pequot Ventures, where he co-led the life sciences investment practice, as well as served as the Managing Member of the Delta Opportunity Fund at Diaz & Altschul Capital Management. He has significant life sciences operations experience, including senior executive positions at Valentis, Boehringer Mannheim (acquired by Roche) and Sandoz (now Novartis). Mr. Enright currently serves on the boards of Aptinyx, CuraSen Therapeutics, Dascena, Epirium Bio, Jazz Pharmaceuticals (JAZZ), Orbus Therapeutics, Rivus Pharmaceuticals and Vera Therapeutics. Mr. Enright holds an MBA from the Wharton School of Business at the University of Pennsylvania and a Bachelor of Science in Biological Sciences from Stanford University.

Dr. Lam is Managing Director, Head of Biotech Private Equity at Ally Bridge Group, a leading global life science-dedicated investment group, where he leads private equity therapeutics investments including Arbor Biotechnologies, Shoreline Biosciences and Sonoma Biotherapeutics. Dr. Lam has over 15 years of biopharma-focused experience across industry, equity research and investment banking. He joined Ally Bridge Group in 2021 from Intercept Pharmaceuticals, where he was Senior Director of Business Development. Prior to joining Intercept, Dr. Lam served as Vice President of Healthcare Investment Banking at Jefferies, where he completed over 30 biopharma financing and M&A transactions, and as an equity research associate at BMO Capital and Canaccord Genuity, where he covered biotech. Before his time on Wall Street, Dr. Lam spent a decade in medical affairs at several biotech companies including Celgene and Shire. He holds a PharmD from Long Island University and an MBA from Drexel University.

Dr. Mehta is a Therapeutics Analyst on the Avidity Partners private investment team. Prior to joining Avidity Partners, she was a Director at Pfizer Oncology, where she was a key member of the Business Development team responsible for several preclinical and clinical-stage licensing and acquisition opportunities. Dr. Mehta also served as Alliance Manager for Pfizer Oncology and spent time at Navigant Consulting in the Life Sciences practice. Dr. Mehta holds a PhD in Cancer Biology and Pharmacology from the University of Medicine and Dentistry of New Jersey and was a National Science Foundation fellow.

Mr. Takhar is a Senior Managing Director and Head of Life Sciences investing at Matrix Capital Management, where he leads and oversees key portfolio investments. Before joining Matrix, he spent time working for High Vista Strategies, Goldman Sachs Investment Strategies and Moody’s Investor Service. Mr. Takhar received a Bachelor of Science in Economics and Mathematics from the Massachusetts Institute of Technology.

Dr. Hutchins is an Associate at Omega Funds. She focuses on private company investing, with an emphasis on oncology and immunology. Prior to joining Omega Funds in 2020, Dr. Hutchins advised and led scientific strategy and vetted healthcare solutions for an emerging venture of the American Heart Association. She also worked as an independent consultant for TreMonti Consulting, where she performed market analyses, evaluated early-stage inventions, and advised clients on partnering for commercialization and in-licensing opportunities. In addition, she previously mentored entrepreneurs and startups in science and technology as an angel investor with Pipeline Angels. Dr. Hutchins earned her PhD in Immunology from Brown University, completed a postdoctoral fellowship at UT Southwestern Medical Center, and holds a Bachelor of Science in Biology from the University of North Carolina at Chapel Hill.

Dr. Kumar is a Vice President of Biotech Private Equity at Ally Bridge Group. With over a decade of biopharma-focused experience, Dr. Kumar has developed expertise across the drug development timeline, including venture capital, corporate strategy, patent strategy, IP licenses and collaborations, IP litigation, commercial contracts, M&A transactions, and FP&A and BD finance. Prior to joining Ally Bridge Group, Dr. Kumar was an attorney at Goodwin Procter in its Life Sciences practice, where he executed complex corporate transactions for biopharma companies. He also practiced law at Morrison & Foerster and McDermott Will & Emery. Additionally, Dr. Kumar gained valuable experience at MPM Capital and Boston University’s technology transfer office during his law school tenure. He began his career as a Financial Analyst at Takeda Pharmaceuticals. Dr. Kumar holds a Bachelor of Science and a PharmD from Northeastern University, and a JD from Boston University.

Mr. Sebban is the Founder and Managing Partner of Eckuity Capital, a healthcare focused growth equity fund with offices in New York, London and Paris. With over 10 years of successful experience in the Venture Capital space, having worked at top-tier firms across Europe and Asia, Mr. Sebban co-founded New-York based Forepont Capital Partners, a leading healthcare venture fund with a focus on Neurology and BCI. Mr. Sebban developed strategic relationships in Europe, the Middle East and Asia and has been instrumental in developing portfolio companies’ business and in originating and overviewing deals. Whilst at Forepont, Mr. Sebban led transactions that have generated over $500 million of shareholder value and three exits in less than five years. Mr. Sebban started his career in Goldman Sachs’ investment banking team in London, covering M&A and capital raising activities within the healthcare sector. He holds a Master of Science in Management from the London School of Economics and Political Science (LSE) and a Master of Science in Management from HEC Paris.

Ms. Sigurdson is a Vice President at Matrix Capital Management where she focuses on public and private life sciences investments. Prior to joining Matrix, Ms. Sigurdson spent time working at ClearView Healthcare Partners as a Senior Consultant. She received a Bachelor of Arts in Human Developmental and Regenerative Biology at Harvard University.

Dr. Wang is a Vice President at Longitude Capital. Prior to joining the company in 2022, Dr. Wang served as the Senior Director of Strategy & Corporate Development at Dascena, a Longitude portfolio company. She also served as an Engagement Manager at L.E.K. Consulting, where she advised life sciences companies on drug development, commercial and portfolio strategy. Dr. Wang holds a PhD in Chemical Biology from the University of California, Berkeley and a Bachelor of Arts in Chemical and Physical Biology from Harvard University.

Mr. Yerrabolu is an Analyst for Woodline Partners. Most recently, Mr. Yerrabolu was responsible for managing public and private biopharmaceutical subsidiary companies at Roivant Sciences. Prior to that, Mr. Yerrabolu was an investment banker at MTS Health Partners, where he primarily focused on life sciences M&A, private placements and strategic advisory. Mr. Yerrabolu graduated from the University of Pennsylvania, earning a Bachelor of Science in Economics (Finance concentration) from the Wharton School and a Bachelor of Arts in Biology from The College of Arts and Sciences.